![ECOG-ACRIN logo[19516]275×75](https://blog-ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
August 25, 2023
Summaries of recently published ECOG-ACRIN research results
June 30, 2023
This phase 2 trial is testing how well FDG-PET/CT imaging can predict response to standard-of-care neoadjuvant therapy in patients with HER2-positive breast cancer
February 10, 2023
Even as screening mammography volumes remain below pre-pandemic levels, TMIST continues to enroll women at a strong pace
October 13, 2022
Research results in breast and kidney cancer; recognition of key colleagues; and a sneak peek of the Fall 2022 Group Meeting
October 13, 2022
Summaries of recently published ECOG-ACRIN research results
October 13, 2022
Summaries and links to timely information about research results in medical journals, recognition of research leaders, and more
April 15, 2022
Enrollment doubles in past 17 months due to specific efforts — Black participation rises above 20%
April 15, 2022
This study aims to determine if it is safe to omit adjuvant chemotherapy after surgery for patients with pathologic complete response (pCR) after 12 weeks of pre-operative treatment
April 15, 2022
Summaries and links to timely information about research results in medical journals, recognition of research leaders, and more
January 26, 2022
Hopes for a return to normalcy in 2022—plus, recent qualitative research identifies surprising barriers to the long-term control of breast cancer
January 26, 2022
Mary Lou Smith and colleagues at the Research Advocacy Network recently explored how well patients with early-stage breast cancer understand risk of recurrence
December 22, 2021
The co-chairs reflect on key 2021 accomplishments, and share their thanks and best wishes for a happy New Year